**A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)**

**Patiëntenaam:**

**Geboortedatum:**

**Inclusion Criteria**

* **Inc 1** Participant must be ≥ 18 years of age at the time of signing the informed consent.
* **Inc 2** Documentation of IgAN diagnosis established on kidney biopsy obtained any time prior to or during the Screening Period (Section 8.1.5).
* **Inc 3** UPCR ≥ 0.75 g/g or UP ≥1 g/day from the mean of two 24-hour urine collections during Screening as described in Section 8.2.1.
* **Inc 4** "Estimated GFR ≥ 30 mL/min/1.73 m^2 at Screening as calculated by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) (Section 8.2.3).
	+ an extra Cohort; a candidate needs first an approval of the sponsor: eGFR 20-29 mL/min/1.73 m^2 at Screening. A kidney biopsy is required within 6 months prior to Screening or during the Screening Period. Kidney biopsy report must demonstrate < 75% each of interstitial fibrosis, tubular atrophy, and glomerular sclerosis.
* **Inc 5** Presence of hematuria as defined by a positive result on urine dipstick for blood or ≥ 5 red blood cells (RBCs)/high power field microscopy on urine sediment during or within 3 months of Screening (Section 8.2.2).
* **Inc 6** Body weight ≥ 30 kg at Screening
* **Inc 7** Male or female
* **Inc 8** Agree to follow protocol-specified contraception guidance as outlined in Section 10.5
* **Inc 9** Capable of giving signed informed consent as described in Section 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
* **Inc 10** Adherence to and compliance with stable and maximum allowed or tolerated RASI (ACEI and/or ARB) dose for ≥ 3 months prior to Screening with no planned change during Screening through Week 106. Participants with intolerance to RASI medications may be included (Section 6.9).
* **Inc 11**  Participants who are on an SGLT2I, ERA, or MRA must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to Screening with no planned change through Week 106 (Section 6.9).
* **Inc 12** Controlled blood pressure of < 140/90 mmHg at Screening.
* **Inc 13** To reduce the risk of meningococcal infection (\_N meningitidis\_), all participants must be vaccinated against meningococcal infection from serogroups A, C, W, Y (and B where available) within 3 years prior to study intervention on Day 1. If vaccination occurs < 2 weeks from Day 1, the participant will receive prophylactic antibiotics for at least 2 weeks after initial meningococcal vaccination.

**Exclusion Criteria**

* **Exc 1** Diagnosis of rapid progressive glomerulonephritis as measured by eGFR loss ≥ 50% over a period of 3 months prior to Screening.
* **Exc 2** Secondary IgAN (eg, due to systemic lupus erythematosus (SLE), cirrhosis, or celiac disease).
* **Exc 3** Concomitant clinically significant renal disease other than IgAN.
* **Exc 4** Uncontrolled diabetes mellitus with glycosylated hemoglobin (HbA1c) > 8.5%.
* **Exc 5** Clinically active Henoch-Schonlein purpura (IgA vasculitis) requiring ongoing systemic immunosuppressive therapy at Screening.
* **Exc 6** History of kidney transplant or planned kidney transplant during the Treatment Period.
* **Exc 7** History of other solid organ (heart, lung, small bowel, pancreas, or liver) or bone marrow transplant; or planned transplant during the Treatment Period or open-label Exploratory Cohort, except for corneal transplant.
* **Exc 8** Body mass index ≥ 38 kg/m^2 .
* **Exc 9** Splenectomy or functional asplenia.
* **Exc 10** History of Neisseria meningitidis\_ infection.
* **Exc 11** Known history of human immunodeficiency virus (HIV) infection as documented by HIV-1/HIV-2 testing or positive HIV-1/HIV-2 antibody titer at Screening.
* **Exc 12** Evidence of hepatitis B (positive hepatitis surface antigen [HBsAg] or positive core antibody (anti-HBc) with negative surface antibody [anti-HBs]) or hepatitis C viral infection (HCV antibody positive, except for participants with documented successful treatment. If locally available, sustained virologic response should be documented or established at Screening).
* **Exc 13** Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.
* **Exc 14** Drug or alcohol abuse or dependence within 1 year prior to Screening that interferes with ability to participate in the clinical study.
* **Exc 15** History of malignancy within 5 years of Screening, except for nonmelanoma skin cancer or carcinoma in situ of the cervix that has been treated with no evidence of recurrence.
* **Exc 16** Hypersensitivity to any ingredient contained in the study intervention, including to murine proteins.
* **Exc 17** Systemic corticosteroid therapy (eg, prednisone or prednisone equivalent) ≥ 10 mg/day or any other systemic immunosuppression for the treatment of IgAN within 6 months of Screening (except short course steroids [approximately 14 days] for non-IgAN treatment) (Section 6.9).
* **Exc 18** Ongoing budesonide therapy or budesonide therapy > 3 months duration within 6 months prior to Screening.
* **Exc 19** Biologic(s) for the treatment of IgAN ≤ 6 months prior to Screening.
* **Exc 20** Tripterygium Wilfordii for the treatment of IgAN within 6 months prior to Screening (Section 6.9).
* **Exc 21** Currently receiving or previously received a complement inhibitor within 30 days or 5 half-lives, whichever is longer, prior to Screening.
* **Exc 22** Participation in another investigational drug or investigational device study within 30 days before Screening or within 5 half-lives of that investigational product, whichever is greater.
* **Exc 23** Pregnant, breastfeeding, or intending to conceive during the study.
* **Exc 24** Inability to travel to the clinic for specified visits during the study or fulfill the logistical requirements of study intervention administration.
* **Exc 25** Participant is imprisoned or lawfully retained at an institution via administrative or judicial order.
* **Exc 26** Participant is an employee or directly related to an employee of Alexion, AstraZeneca, or the institution/investigational site.